Cyclerion Therapeutics (CYCN) Retained Earnings (2019 - 2025)
Cyclerion Therapeutics (CYCN) has disclosed Retained Earnings for 7 consecutive years, with -$270.2 million as the latest value for Q3 2025.
- For Q3 2025, Retained Earnings changed N/A year-over-year to -$270.2 million; the TTM value through Sep 2025 reached -$270.2 million, changed N/A, while the annual FY2023 figure was -$264.4 million, 2.03% down from the prior year.
- Retained Earnings hit -$270.2 million in Q3 2025 for Cyclerion Therapeutics, roughly flat from -$269.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$16000.0 in Q2 2023 and bottomed at -$270.2 million in Q3 2025.
- Average Retained Earnings over 5 years is -$144.7 million, with a median of -$193.0 million recorded in 2021.
- Year-over-year, Retained Earnings surged 99.99% in 2023 and then tumbled 1680656.25% in 2025.
- Cyclerion Therapeutics' Retained Earnings stood at -$23000.0 in 2021, then plummeted by 1126656.52% to -$259.2 million in 2022, then fell by 2.03% to -$264.4 million in 2023, then fell by 1.09% to -$267.3 million in 2024, then decreased by 1.09% to -$270.2 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods came in at -$270.2 million, -$269.2 million, and -$268.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.